-
乳腺癌是女性常见的恶性肿瘤,占女性恶性肿瘤的第一位,全世界每年约120万妇女患乳腺癌,50万人死于乳腺癌[1]。许多临床研究报道,乳腺癌骨转移的发生率比肺和肝脏的肿瘤转移要高许多,约占所有乳腺癌患者的70%[2]。女性乳腺癌患者常接受内分泌辅助治疗,体内雌激素水平下降,随后出现骨钙质减少和骨质疏松,由于骨质疏松及转移性骨肿瘤会导致骨折,严重影响中老年妇女的健康和寿命,因此,它的防治已成为迫切需要解决的问题[3]。临床上乳腺癌传统的治疗方法有药物止痛、放疗、化疗及手术等,但疗效不佳[4]。本研究采用89SrCL2联合唑来膦酸治疗激素依赖型乳腺癌转移性骨肿瘤,疗效较为满意,现将结果报道如下。
89SrCL2与唑来膦酸联合治疗乳腺癌转移性骨肿瘤的疗效分析
Analysis on the curative effect of combination therapy with zoledronic acid and 89SrCL2 on bone tumor with breast cancer metastasis
-
摘要:
目的 探讨放射性核素二氯化锶(89SrCL2)联合唑来膦酸治疗激素依赖型乳腺癌转移性骨肿瘤的临床疗效。 方法 回顾性分析64例激素依赖型乳腺癌转移性骨肿瘤患者的临床资料,将所有患者分为3组: 89SrCL2治疗组22例; 唑来膦酸治疗组21例; 89SrCL2联合唑来膦酸治疗组21例; 观察治疗后转移病灶疗效、骨痛缓解情况、生活质量状况、骨髓抑制反应情况。 结果 89SrCL2治疗骨转移病灶有效率为36.4%(8/22),视觉模拟评分下降率为77.3%(17/22),全身状况KPS评分提高率为63.6%(14/22),27.2%(6/22)的患者出现骨髓抑制反应; 唑来膦酸治疗后骨转移病灶有效率为33.3%(7/21),视觉模拟评分下降率为71.4%(15/21),全身状况KPS评分提高率为52.4%(11/21),19.0%(4/21)的患者出现骨髓抑制反应; 89SrCL2联合唑来膦酸治疗骨转移病灶有效率为42.9%(9/21),视觉评分下降率为90.5%(19/21),全身状况KPS评分提高率为90.5%(19/21),33.3%(7/21)的患者出现骨髓抑制反应。 结论 89SrCL2联合唑来膦酸对激素依赖型乳腺癌转移性骨肿瘤的疗效明显,不良反应小,联合治疗效果优于89SrCL2和唑来膦酸单独治疗。 Abstract:Objective To discuss the clinical effects of radionuclide 89SrCL2 combined zoledronic acid treatment for hormone dependent breast neoplasm metastatic osteoma. Methods Clinical data of 64 patients with hormone dependent breast neoplasm metastatic osteoma were analyzed retrospectively.All of these patients were divided into 3 groups: one group of 22 cases treated with 89SrCL2(89SrCL2 group); another group of 21 cases treated with zoledronic acid(zoledronic acid group); and the last group of 21 cases treated with 89SrCL2 and zoledronic acid(combination group).Then patients′ metastatic lesion curative effects, the condition of bone pain remission, quality of life and bone marrow inhibitory reaction after treatment were observed. Results The effective rate, visual analogue scale decline rate, whole body KPS score increase rate and bone marrow inhibitory reaction rate of the 89SrCL2 group were 36.4%(8/22), 77.3%(17/22), 63.6%(14/22), 27.2%(6/22), and which were 33.3%(7/21), 71.4%(15/21), 52.4%(11/21), 19.0%(4/21) and 42.9%(9/21), 90.5%(19/21), 90.5%(19/21), 33.3%(7/21) in zoledronic acid group and combination group respectively. Conclusion 89SrCL2 combined with zoledronic acid on treating hormone dependent breast neoplasm metastatic osteoma has significant curative effect, and can relieve pain with less adverse reactions, and the combined treatment effects are better than that of 89SrCL2 or zoledronic acid alone. -
Key words:
- Breast neoplasms /
- Neoplasms metastasis /
- Osteoms /
- 89SrCL2 /
- Zoledronic acid
-
[1] Kozlow W, Guise TA.Breast cancer metastasis to bone: mechanisms of osteolysis and implications for therapy[J].J Mammary Gland Biol Neoplasia, 2005, 10(2): 169-180. [2] Mundy GR.Metastasis to bone: causes, consequences and therapeutic opportunities[J].Nat Rev Cancer, 2002, 2(8): 584-593. [3] 吕靖, 马彩玲.绝经后骨质疏松症的治疗新进展[J].医学综述, 2007, 13(1): 62-63.
[4] 刘鹏熙, 周瑞芳, 许锐, 等.唑来膦酸与帕米膦酸二钠治疗乳腺癌骨转移性疼痛的近期疗效观察[J/OL].中华乳腺病杂志: 电子版, 2008, (4): 402-406[2014-01-13].http://cjbd.xnyy.cn/cn/index.asp.
[5] Finlay IG, Mason MD, Shelley M.Radioisotopes for the palliation of metastatic bone cancer: a systematic review[J].Lancet Oncol, 2005, 6(6): 392-400. [6] 潘中允.放射性核素治疗学[M].北京:人民卫生出版社, 2006: 217.
[7] 翟士军, 万卫星, 吴娜静, 等.89SrCL2联合唑来膦酸治疗转移性骨肿瘤的疗效观察[J].中国辐射卫生, 2013, 22(4): 404-406.
[8] Body JJ.Clinical research update; zoledronate[J].Cancer, 1997, 80(8 Suppl): S1699-1701. [9] Skerjance A, Berenson J, Hsu C, et al.The pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with varying degrees of renal function[J].J Clin Pharmacol, 2003, 43(2): 154-162. [10] Neville-Webbe HI, Coleman RE.The use of zoledronic acid in the management of metastatic bone disease and hypercalcaemia[J].Palliat Med, 2003, 17(6): 539-553. [11] Matsumoto S, Kimuta S, Seqawa H, et al.Efficacy of the third-generation bisphosphonate, zoledronic acid alone and combined with anti-cancer agents against small cell lung cancer cell lines[J].Lung Cancer, 2005, 47(1): 31-39. [12] Croucher P, Jagdev S, Coleman R.The anti-tumor potential of zoledronic acid[J].Breast, 2003, 12 Suppl 2: S30-36.
计量
- 文章访问数: 2247
- HTML全文浏览量: 1063
- PDF下载量: 4